Travere Therapeutics (NASDAQ:TVTX) Insider Sells $121,433.85 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 2,763 shares of Travere Therapeutics stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $121,433.85. Following the completion of the transaction, the insider owned 115,474 shares in the company, valued at approximately $5,075,082.30. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Down 0.1%

Shares of Travere Therapeutics stock opened at $42.60 on Friday. The company has a market cap of $3.96 billion, a P/E ratio of -185.21 and a beta of 1.13. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $48.61. The firm has a fifty day moving average of $32.83 and a two-hundred day moving average of $32.94.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the firm earned ($0.47) earnings per share. The business’s quarterly revenue was up 55.6% compared to the same quarter last year. On average, analysts forecast that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TVTX. Wedbush boosted their target price on Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wells Fargo & Company raised their price target on Travere Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup lifted their price target on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings cut Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Finally, Guggenheim raised their target price on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.83.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Travere Therapeutics by 13.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after acquiring an additional 6,831 shares in the last quarter. Norges Bank acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth approximately $1,051,000. First Trust Advisors LP purchased a new position in Travere Therapeutics in the 2nd quarter valued at approximately $3,538,000. Cresset Asset Management LLC increased its stake in Travere Therapeutics by 26.5% in the 2nd quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock valued at $427,000 after purchasing an additional 6,047 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the last quarter.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.